Pfizer Boost FY24 Outlook - Update

RTTNews | 148 दिनों पहले
Stocktwits
Pfizer Boost FY24 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.45 to $2.65 per share on revenues between $59.5 billion and $62.5 billion, with revenues of about $8.5 billion for Comirnaty, about $5 billion for Paxlovid and about $3.5 billion from legacy Seagen.

Previously, the company expected adjusted earnings in the range of $2.15 to $2.35 per share on revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $2.38 per share on revenues of $60.70 billion for the year. Analysts' estimates typically exclude special items.

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer now expects to achieve full-year 2024 operational revenue growth of 9 to 11 percent, compared to 2023 revenues, up from 8 to 10 percent provided on January 30, 2024.

The company has launched a manufacturing optimization program with anticipated cost savings of approximately $1.5 billion by the end of 2027.

The company is also on track to deliver at least $4 billion in net cost savings by end of 2024 from previously announced cost realignment program.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

टैग: PFE
Stocktwits
read more
Pfizer Launches Digital Platform PfizerForAll

Pfizer Launches Digital Platform PfizerForAll

Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews | 120 दिनों पहले
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews | 125 दिनों पहले
Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron

Pfizer Advances Once-Daily Formulation Of Oral GLP-1 Receptor Agonist Danuglipron

Drug major Pfizer, Inc. (PFE) announced Thursday that the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, based on results from the ongoing pharmacokinetic study (NCT06153758).
RTTNews | 167 दिनों पहले
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews | 216 दिनों पहले
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 226 दिनों पहले
Pfizer Boost FY24 Adj. EPS Outlook - Update

Pfizer Boost FY24 Adj. EPS Outlook - Update

While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
RTTNews | 238 दिनों पहले
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews | 377 दिनों पहले
उपकरण
आर्थिक कैलेंडर
Market Hours
Interest Rates
Holidays Calendar
फोरेक्स मार्केट
फोरेक्स वॉलटीलिटी (अस्थिरता)
फोरेक्स कोरीलैशन
फोरेक्स के समाचार
forex analysis
सीओटी डाटा
लिक्विडिटी
फॉरेक्स कैल्कुलेटर
फोरेक्स के हीट का नक्शा
Indicators Heatmap
कम्युनिटी
कम्युनिटी
सिस्टमों
सर्व प्रसिद्ध सिस्टमों
रणनीतियां
प्रतियोगिता
फोरेक्स चार्टों
फोरेक्स भावना
आउटलुक इंडिकेटर
रीव्यूज़
ब्रोकरों
Prop Trading Firms
वी पी एस की सेवाएं
सिगनल को उपलब्ध कराने वाले
EA प्रोग्रामिंग की सेवाएं
Affiliate Programs
PAMM ब्रोकर की सेवाएं
रीबैट कार्यक्रम की सेवाएं
ट्रेडिंग के प्लैटफॉर्म
माहिर सलाहकारों
क्रिप्टो एक्सचेंज
Trading Courses
ब्रोकरों
फोरेक्स स्प्रेड
फोरेक्स ब्रोकर के क्वोट-चिह्न.
फोरेक्स ब्रोकरों के स्वाप
फोरेक्स ब्रोकर वॉल्यूम
फोरेक्स ब्रोकर की पदोन्नति Broker News
प्लेटफॉर्म
विजेट
विशेषताएं
API
RSS
Stock Portfolio
Affiliate Software
एडवांस चार्ट
सहयोग
अधिकतम पूछे जाने वाले प्रश्न (एफएक्यू )
सहायता
हमसे संपर्क करें
बग को रिपोर्ट करें!
बारे में
ब्लॉग
&प्रतिलिपि; 2024 Myfxbook Ltd. सर्वाधिकार सुरक्षित.
उच्च जोखिम चेतावनी: फॉरन एक्सचेंज ट्रेडिंग में उच्च स्तर का खतरा होता है जो हर निवेशकों के लिए सही नहीं हो सकता. लीवरेज अधिकतम खातर और हानि के अनावरण को उत्पन्न करता है. इससे पहले कि आप निर्णय लें फॉरन एक्सचेंज में ट्रेड करने का, ध्यान अपने निवेश के उद्देश्यों, अनुभव स्तर, और खतरा उठाने की सहिष्णुता पर विचार करें. आप कुछ या अपनी प्रारंभिक निवेश को खो सकते हैं. बिल्कुल भी उस पैसे को निवेश ना करें जो आप खोने को बर्दाश्त नहीं कर सकते. अपने आप को शिक्षित करें उन खतरों से जो फॉरन एक्सचेंज ट्रेडिंग से संबंधित हैं, और सलाह लें किसी स्वतंत्र आर्थिक या कर सलाहकार से अगर आपके पास कोई भी प्रश्न हैं तो. कोई भी डाटा या जानकारों जो दी जाती है वे केवल सूचनात्मक उद्देश्यों के लिए है, और यब ट्रेडिंग आशय या सलाह पर नियत नहीं है. पिछले निष्पादन भविष्य के परिणामों के लिए परियाचक नहीं हैं.